Key result
Chronic XNT prevents elevated right ventricular pressure, hypertrophy, and vascular remodeling in rats.
Why the study?
An activated renin angiotensin system is proposed to contribute to pulmonary hypertension, and while angiotensin-converting enzyme 2 (ACE2) regulates lung pathophysiology, whether activating endogenous ACE2 can prevent pulmonary hypertension was uncertain.
Does XNT prevent pulmonary hypertension in a monocrotaline-induced rat model?
Does XNT prevent pulmonary hypertension in a monocrotaline-induced rat model?
Answers are grounded in this paper and cite their sources.
Activation of ACE2 by the small molecule XNT prevents the development of pulmonary hypertension in a rat model, suggesting a potential therapeutic target.
Rationale It has been proposed that an activated renin angiotensin system (RAS) causes an imbalance between the vasoconstrictive and vasodilator mechanisms involving the pulmonary circulation leading to the development of pulmonary hypertension (PH). Recent studies have indicated that angiotensin-converting enzyme 2 (ACE2), a member of the vasoprotective axis of the RAS, plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Based on these observations, we propose the hypothesis that activation of endogenous ACE2 can shift the balance from the vasoconstrictive, proliferative axis (ACE-Ang II-AT1R) to the vasoprotective axis [ACE2-Ang-(1–7)-Mas] of the RAS, resulting in the prevention of PH. Objectives We have taken advantage of a recently discovered synthetic activator of ACE2, XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one), to study its effects on monocrotaline-induced PH in rats to support this hypothesis. Methods The cardiopulmonary effects of XNT were evaluated in monocrotaline-induced PH rat model. Measurements and Main Results A single subcutaneous treatment of monocrotaline in rats resulted in elevated right ventricular systolic pressure, right ventricular hypertrophy, increased pulmonary vessel wall thickness, and interstitial fibrosis. These changes were associated with increases in the mRNA levels of renin, ACE, angiotensinogen, AT1 receptors, and proinflammatory cytokines. All these features of PH were prevented in these monocrotaline-treated rats by chronic treatment with XNT. In addition, XNT caused an increase in the antiinflammatory cytokine, IL-10. Conclusions These observations provide conceptual support that activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling PH.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2009) studied Monocrotaline-induced pulmonary hypertension. XNT (synthetic ACE2 activator) vs. Untreated monocrotaline-induced PH rats was evaluated on Right ventricular systolic pressure, right ventricular hypertrophy, pulmonary vessel wall thickness, and interstitial fibrosis. Chronic XNT treatment prevented elevated right ventricular systolic pressure, hypertrophy, vessel wall thickening, and fibrosis in monocrotaline-treated rats (no quantitative statistics in abstract).
Synapse has enriched 10 related papers. Consider them for comparative context: